GHRP-2 vs Ipamorelin: when the older peptide still wins
May 29, 2026 · 6 min read · By Strength Peptide Editors
The peptide community treats Ipamorelin as the gold-standard GHRP — cleanest receptor binding, lowest side-effect profile, the default pick for GH-pulse work. GHRP-2 is the older sibling that mostly gets recommended against because of "prolactin and cortisol issues." That framing is mostly right but slightly too dismissive. GHRP-2 produces a measurably stronger GH pulse than Ipamorelin at typical doses, costs noticeably less per vial, and has a real use case for users who can manage the side-effect tradeoffs. This post walks through the comparison honestly.
For broader GHRP context see GHRP-2 vs GHRP-6 vs Ipamorelin and GH stack: Ipamorelin and CJC-1295.
What each molecule is
Both peptides bind the GHS-R1a receptor (the ghrelin receptor) and stimulate GH release from the pituitary. They're in the same pharmacological class.
GHRP-2 is a hexapeptide developed in the 1990s. Sequence: D-Ala-D-Nal-Ala-Trp-D-Phe-Lys-NH2. It's the second-generation GHRP, following GHRP-6.
Ipamorelin is a pentapeptide developed in the late 1990s specifically to retain GH-releasing activity while reducing off-target effects. Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2.
Both work. The difference is in how cleanly they work.
The side-by-side
| Feature | GHRP-2 | Ipamorelin |
|---|---|---|
| Receptor binding | GHS-R1a | GHS-R1a (more selective) |
| GH pulse magnitude | Larger | Smaller |
| Prolactin elevation | Mild–moderate | Negligible |
| Cortisol elevation | Mild–moderate | Negligible |
| Hunger increase | Mild | Negligible |
| Half-life | ~30 min | ~2 hours |
| Typical dose | 100–300 mcg | 200–300 mcg |
| Cost per dose | Lower | Higher |
| Desensitization risk | Moderate | Lower |
| Best paired with | CJC-1295 (no DAC) | CJC-1295 (no DAC) |
| Suitable for first cycle | Less so | Yes |
The headline tradeoff: GHRP-2 produces more GH per unit dose, but with non-zero collateral effects on prolactin and cortisol. Ipamorelin produces less GH per unit dose, but virtually no off-target effects.
When GHRP-2 actually wins
The legitimate use cases:
Cost-sensitive users with stable side-effect profiles. GHRP-2 is typically 30–50% cheaper per equivalent dose than Ipamorelin. For users running multi-month protocols who tolerate the mild prolactin/cortisol bumps, the cost differential adds up.
Users wanting larger GH pulses. Bodybuilders and lifters running protocols where peak GH pulse magnitude matters more than receptor-selectivity may prefer GHRP-2. The pulse really is larger.
Hardgainers needing modest appetite stimulation. The mild hunger increase from GHRP-2 (much less than GHRP-6) can be a feature rather than a bug for users struggling to eat enough.
Users on monitored TRT/HRT protocols. Patients already on clinician-managed hormone protocols often have prolactin and cortisol monitored anyway. The marginal increases from GHRP-2 are visible in standard panels and can be managed in that context.
Old-school protocol continuity. Some experienced lifters have running successful protocols on GHRP-2 for years and don't need to switch.
When Ipamorelin wins
The legitimate Ipamorelin use cases (which is most users):
First GH peptide cycle. The cleaner profile reduces learning curve and isolates the GH-axis variable from confounding side effects.
Stable long-term use. Lower desensitization and cleaner profile make Ipamorelin more sustainable for chronic use.
Users sensitive to prolactin or cortisol effects. Anyone with PCOS, pituitary history, adrenal concerns, or related conditions should start with the cleanest option.
Stacking with other GH-axis peptides. When combining with CJC-1295, Sermorelin, or Tesamorelin, the GHRP partner with the smallest side-effect surface produces the cleanest overall protocol.
Female users. The prolactin sensitivity is generally higher in women and Ipamorelin is the safer first choice.
For the women's framing see strength peptides for women: dosing and stacks.
The prolactin and cortisol issue, honestly
The "GHRP-2 raises prolactin and cortisol" framing is real but often overstated. At typical doses (100–300 mcg per injection), the elevations are:
- Prolactin: modest, usually within normal range. Sustained chronic use can push toward upper-normal but rarely outside.
- Cortisol: mild, transient. Returns to baseline between injections.
What this means in practice:
- For most healthy users, the elevations are not clinically significant
- For users with prolactin-sensitive conditions, the elevations matter
- For monitoring purposes, baseline + cycle-mid panels show whether the elevations are within your acceptable range
- Combining GHRP-2 with other prolactin-elevating compounds (some SSRIs, antipsychotics, opioids) compounds the issue
For monitoring frame see baseline labs before a cycle and cardiovascular markers on peptide cycles.
Protocol comparison
A typical GHRP-2 + CJC-1295 (no DAC) protocol:
- GHRP-2 200 mcg + CJC-1295 100 mcg, SubQ, 2× per day (morning fasted + pre-bed)
- 8–10 week cycle, 4-week break
- Monitor IGF-1, prolactin, cortisol at 4 weeks and end of cycle
A typical Ipamorelin + CJC-1295 (no DAC) protocol:
- Ipamorelin 200 mcg + CJC-1295 100 mcg, SubQ, 1–2× per day
- 12-week cycle, 6-week break
- Monitor IGF-1 at 4 weeks and end of cycle
The Ipamorelin protocol is more sustainable for chronic use. The GHRP-2 protocol may produce more pronounced results per cycle at lower cost.
For detailed protocol see Ipamorelin protocol and GH stack: Ipamorelin and CJC-1295.
What to track if you choose GHRP-2
If GHRP-2 is the right pick for your situation, the monitoring is slightly more involved:
| Marker | Frequency | Why |
|---|---|---|
| IGF-1 | Baseline, 4 weeks, end of cycle | Confirms GH pulse efficacy |
| Prolactin | Baseline, 8 weeks | Detects clinically meaningful elevation |
| Cortisol | Baseline, 8 weeks | Same |
| Fasting glucose | Baseline, end of cycle | Standard GH-axis check |
| CBC | Baseline, end of cycle | Standard |
Compared to Ipamorelin (where IGF-1 + glucose is usually sufficient), GHRP-2 warrants the added prolactin and cortisol checks.
The cost angle in practice
A typical year of GH-axis peptide use at moderate doses:
| Protocol | Approximate annual cost (research-chemical sourcing) |
|---|---|
| GHRP-2 + CJC-1295 (no DAC) | $400–700 |
| Ipamorelin + CJC-1295 (no DAC) | $700–1200 |
| Tesamorelin alone | $800–1500 |
| CJC-1295 with DAC + Ipamorelin | $600–1000 |
The differential is real but not transformative for users who can afford either. For users where cost is the binding constraint, GHRP-2 unlocks GH-axis protocols that would otherwise be out of reach.
For broader cost frame see cost-effective peptide protocols.
The honest framing
Ipamorelin remains the right default for most users — newer, cleaner, easier to manage. GHRP-2 is not "deprecated"; it's the right pick for a smaller but real population: cost-sensitive users who tolerate mild prolactin/cortisol effects, experienced lifters wanting larger GH pulses, and users continuing successful long-term protocols.
The mistake to avoid is treating "everyone should use Ipamorelin" as universal advice. The mistake to also avoid is treating "GHRP-2 raises prolactin and cortisol" as a disqualifying problem rather than a manageable tradeoff. The right answer depends on your specific situation.
Related reading
Free weekly newsletter
Get the strength peptide highlights, weekly.
One short email a week — new guides, study readouts, supply updates, and dosing tips. Plain-English, no spam.
Unsubscribe anytime. We never share your email.